LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway

Ding, Shimei; Qü, Wei; Yang, Jiao; Zhang, Jing; Zhang, Chunhong; Dang, Shuangsuo

doi:10.3233/cbm-170777

Cited by 58 publications

(46 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, SNHG12 was also involved in GO:0006260~DNA replication and GO:0000082~G1/S transition of mitotic cell cycle, which suggested that SNHG12 could regulate the cell proliferation. Recent evidences show that lncRNA SNHG12 promotes proliferation and metastasis of osteosarcoma and papillary thyroid carcinoma (34,35), which was consistent with our ndings. The oncogenic role of lncRNA SNHG12 is also determined in cervical cancer (36) and prostate cancer (37).…”

Section: Discussionsupporting

confidence: 93%

Biomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Databiomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Data

Du¹,

Qiao²,

Xie³

2020

Preprint

View full text Add to dashboard Cite

Background: We attempted to discover the biomarker associated with lung cancer metastasis and prognosis.Methods: The mRNA/lncRNA expression profiles were downloaded from the publicly available database, which included three highly metastatic and three weakly metastatic samples. The differentially expressed genes and lncRNAs were analyzed and survival analysis were performed based on the TCGA database. The prognosis associated protein-protein interaction (PPI) network and mRNA-lncRNA coexpression network were constructed followed by the function and pathway enrichment analysis.Results: Total 256 differentially expressed genes and 2 lncRNAs were found to be closely related with prognosis. PPI network was constructed with 222 nodes and 1464 edges. Two modules were divided from PPI network. Genes in Module A were significantly enriched in cell cycle checkpoint, chromosome segregation, and mitotic cell cycle checkpoint. The Module B was closely related with pyridine nucleotide metabolic process, nicotinamide nucleotide metabolic process and carbon metabolism. Coexpression network revealed lncRNA H19 and lncRNA SNHG12 were significant nodes. SNHG12 was closely related with GO:0006260~DNA replication, GO:0055114~oxidation-reduction process and hsa00010:Glycolysis/ Gluconeogenesis. H19 was enriched in GO:0006555~methionine metabolic process, and GO:0046655~folic acid metabolic process.Conclusion: TTK, CCNB1 and lncRNA SNHG12 may be the biomarker associated with metastasis and prognosis of lung adenocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 93%

Biomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Databiomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Data

Du¹,

Qiao²,

Xie³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…27 Subsequently, several scholars confirmed that the expression of CITED1 in thyroid papillary carcinoma was much higher than that in normal thyroid tissue. 28,29 These indicate that CITED1 has potential application value in differentiating PTC from benign thyroid lesions. In this study, we showed that 177 Lu-labeled PNA can specifically aggregate in papillary thyroid carcinoma, and can effectively inhibit tumor growth and prolong the life cycle of nude mice.…”

Section: Discussionmentioning

confidence: 95%

<p>Preparation and SPECT/CT Imaging of <sup>177</sup>Lu-Labeled Peptide Nucleic Acid (PNA) Targeting CITED1: Therapeutic Evaluation in Tumor-Bearing Nude Mice</p>

Li¹,

Zhang²,

Li³

et al. 2020

OTT

View full text Add to dashboard Cite

The expression of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxyterminal domain 1 (CITED1) is upregulated in papillary thyroid carcinoma (PTC) and mediates cell proliferation and migration. To facilitate early diagnosis and monitoring of recurrent or metastatic PTC, we designed 177 Lu-labeled antisense peptide nucleic acid (PNA) targeting CITED1 mRNA to evaluate the therapeutic potential, while analyzing its distribution in nude mice and the characteristics withsingle-photon emission-computed tomography/ computed tomography (SPECT/CT) imaging. Materials and Methods: 177 Lu-DOTA-anti-CITED1-PNA (177 Lu-asPNA) was obtained by indirect labeling. High-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) were used to determine the labeling rate and radiochemical purity. The stability of 177 Lu-asPNA was evaluated by TLC, and the radioactivity count was measured by a γ counter to calculate its uptake capacity in K1 cells. To analyze the distribution of 177 Lu-asPNA in body tissues and organs of nude mice, static single-photon emission-computed tomography (SPECT) imaging and SPECT/CT image fusion were performed. Then, the therapeutic effects of probes were explored by tumor growth curves and survival analysis. Results: Our probe showed a radiochemical purity of 96.5±0.15% at 1 hr and specific activity of 8.7±0.53 MBq/μg. The uptake rate in the 177 Lu-asPNA group was much higher than that in the 177 Lu-DOTA-nonsense-PNA (177 Lu-nonsense-PNA) and 177 Lu-DOTA groups (P<0.05). The biological distribution showed that the tumor/muscle ratio was at its highest at 24 h (4.98±0.34) post-inoculation, with SPECT/CT imaging showing clear tumor development. By measuring tumor volume of tumor-bearing nude mice, the 177 Lu-asPNA group showed a significant difference in tumor size 9 days after injection (P < 0.05). Kaplan-Meier survival curves showed that the overall survival rate in the 177 Lu-asPNA group was significantly different from those in the DOTA-anti-CITED1-PNA (asPNA) and saline groups (P = 0.002, log-rank test). Conclusion: 177 Lu-asPNA was developed successfully, showing a high labeling rate and good stability. SPECT/CT imaging demonstrated tumor growth in nude mice, which was effectively inhibited by our probe, thus prolonging survival.

show abstract

“…There is evidence that lncRNAs can act as molecular scaffolds, sponges or coactivators in tumor scaffolds by interacting with DNA, RNA or proteins [5,31,32] . At present, increasing evidence has shown that the abnormally high expression of SNHG12 plays a carcinogenic role in various malignant tumors [10][11][12][13][14][15][16][17][18][19][26][27][28][29] .…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, in lung cancer, this molecule can inhibit metastasis and epithelial-mesenchymal transition when inhibited [12] . Furthermore, increased SNHG12 not only regulates malignant behavior by activating oncogenes (AMOT, HuR slug/ZEB2) [12,33,34] , signaling pathways (MAPK/Slug, wnt/β-catenin, and Notch signaling pathway) [10,11,29,30,35] and the microRNA-gene axis (miR-125b/STAT3 and miR-101-3p/FOXP1) [27,31,36] but also enhances chemoresistance of tumor cells [31,32,37] . SNHG12 is negative regulation miR-195-5p, miR-320, miR-129, miR-193a-3p, microRNA-199a/b-5p and miR-424-5 [11,14,15,17,26] .…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA SNHG12 is a Potential Diagnostic and Prognostic Biomarker in Various Tumors

Wang

Jiang

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Tumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Although methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. These may lack effective therapeutic targets. This study aimed to evaluate the value of SNHG12 as a biomarker in the prognosis and clinical characteristics of various cancer patients.Methods. We analyzed SNHG12 expression and plotted the survival curves of all cancer samples in the TCGA database using the GEPIA tool. Then, we searched for eligible papers up to April 1, 2019 in databases. Next, the data were extracted from studies examining SNHG12 expression, overall survival and clinicopathological features in patients with malignant tumors. We used Review Manager 5.3 and Stata 15 software to analyze the statistical data.Results. In the TCGA database, abnormally high expression of SNHG12 in tumor samples indicates that the patient has a poor prognosis. Results of meta-analysis is that SNHG12 high expression is related to low overall survival (HR=2.72, 95% CI=1.95-3.8, P<0.00001), high tumor stage (OR=3.94, 95% CI=2.80-5.53, P<0.00001), high grade (OR=2.04, 95% CI=1.18-3.51, P=0.01), distant metastasis (OR=2.20, 95% CI=1.40-3.46, P=0.0006), tumor size (OR=2.79, 95% CI=1.89-4.14, P<0.00001) and lymph node metastasis (OR=2.66, 95%CI=1.65-4.29, P<0.0001).Conclusions. Our study confirmed that the high expression level of SNHG12 is closely related to the clinicopathological characteristics and prognosis of patients and is a new predictive biomarker for various cancer patients.

show abstract

LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway

Abstract: The SNHG12 expression is relatively high in PTC tissues and cells. In-vivo/in-vitro experiments prove that SNHG12 can promote the proliferation and metastasis of PTC cells through influencing the Wnt/β-catenin signaling pathway.

Cited by 58 publications

References 26 publications

Biomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Databiomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Data

Biomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Databiomarkers Associated With Metastasis and Prognosis of Lung Cancer Based on Microarray Data

<p>Preparation and SPECT/CT Imaging of <sup>177</sup>Lu-Labeled Peptide Nucleic Acid (PNA) Targeting CITED1: Therapeutic Evaluation in Tumor-Bearing Nude Mice</p>

Long Noncoding RNA SNHG12 is a Potential Diagnostic and Prognostic Biomarker in Various Tumors

Contact Info

Product

Resources

About